Opendata, web and dolomites

WASABI

Towards the Wider uptake of Arterial Stiffness As a BIomarker for cardiovascular diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 WASABI project word cloud

Explore the words cloud of the WASABI project. It provides you a very rough idea of what is the project "WASABI" about.

complicate    population    individuals    carotid    contexts    signal    business    notably    suitable    questionable    shown    recognised    arteriograph    lower    niche    affordable    cardiologists    bplab    relatively    pulse    estimations    undertaking    pulsepen    elaborate    medical    stiffening    create    plan    everyday    actions    graph    sensor    pressure    vasotens    innovation    property    transform    sphygmocor    move    practitioners    technologies    easier    assemble    cardiovascular    pwv    physicians    complior    stiffness    demonstration    device    artery    hypertension    serial    velocity    mo    arterial    biomarker    measuring    gold    methodology    model    renal    secure    distribute    intellectual    diabetes    rights    appropriate    of    standard    sensors    tool    alternative    mellitus    stage    market    clinical    bil    select    elevated    initiated    either    blood    local    predict    intend    expensive    mainly    aortic    wave    mortality    alam   

Project "WASABI" data sheet

The following table provides information about the project.

Coordinator
ALAM MEDICAL 

Organization address
address: 112 AVENUE DE PARIS
city: VINCENNES
postcode: 94300
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.complior.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-12-01   to  2016-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ALAM MEDICAL FR (VINCENNES) coordinator 50˙000.00

Map

 Project objective

Aortic stiffness is a recognised cardiovascular biomarker and measurement of aortic pulse wave velocity (PWV) is the gold standard methodology to assess large artery stiffening. Elevated aortic PWV has been shown to predict cardiovascular, and in some cases all cause, mortality in individuals with end-stage renal failure, hypertension, diabetes mellitus, as well as in the general population. However, at present, the role of measurement of PWV as a general clinical tool remains to be established, particularly because devices on the market (ALAM Medical Complior, SphygmoCor, Mo-bil-O-Graph, PulsePen, BPLab Vasotens, or Arteriograph) are either complicate to use and relatively expensive, or only provide lower cost estimations whose clinical value is questionable.

That’s why ALAM Medical has initiated an innovation project whose objective is to scale up the use of arterial stiffness as a biomarker, notably by investigating alternative sensors so as to create and distribute an easier to use and more affordable device measuring gold standard aortic stiffness and local carotid stiffness while being suitable for everyday use in numerous medical contexts. By providing a medical device with such characteristics, as well as by undertaking appropriate market awareness actions, we intend to transform our existing niche market, mainly composed of clinical researchers, into a large-scale market composed of clinical practitioners, cardiologists or physicians: arterial stiffness measurements have the potential to move from research to standard medical practice, on the model of blood pressure measurements.

To this aim, during project Phase 1, ALAM Medical will select the most appropriate sensor technology, secure intellectual property rights on sensor and signal processing technologies, assemble pre-serial devices, elaborate a more detailed business plan, and design a large-scale demonstration study (included in project Phase 2).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "WASABI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "WASABI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More